247.85MMarket Cap-3633P/E (TTM)
3.280High3.145Low180.16KVolume3.250Open3.250Pre Close581.00KTurnover0.26%Turnover RatioLossP/E (Static)75.80MShares3.68052wk High3.04P/B224.87MFloat Cap1.08052wk Low--Dividend TTM68.77MShs Float396.060Historical High--Div YieldTTM4.15%Amplitude1.080Historical Low3.224Avg Price1Lot Size
aTyr Pharma Stock Forum
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compar...
No comment yet